Open label, non-comparative, observational study to evaluate the effectiveness, safety and tolerability of valsartan (Diovan®) 160 mg as a starting dose for essential hypertension in an asian population.
- Author:
Norbert Lingling UY
;
Francis M DOMINGO
;
Rafael R CASTILLO
- Publication Type:Others
- Keywords:
Blood PressureAngiotension Ii Receptor BlockerFirst-line MonotherapyValsartan
- MeSH:
Human;
Aged;
Middle Aged;
Adult;
Young Adult;
Adolescent;
Hypertension
- From:
Philippine Journal of Internal Medicine
2008;46(2):87-95
- CountryPhilippines
- Language:English
-
Abstract:
OBJECTIVE: The primary objective of this study was to evaluate the effectiveness of valsartan 160 mg as a starting dose for hypertension based on the percentage of responders, in terms of reduction of diastolic blood pressure (DBP), after 4 weeks treatment.The secondary objectives are to evaluate the percentage of responders - in terms of systolic blood pressure (SBP) - after 4 weeks treatment, the reduction til MsSBP and MsDBP with valsartan 1 60 mg treatment at 4 weeks, control rates (% of patients) with SBP < 140 tnmHg and DBP 160 mmHg or DBP >100 mmHg)including those patients with isolated systolic hypertension (SBP 140 mmHg/DBP
